Clinical experience with the inactivated hepatitis A vaccine, Avaxim 80U Pediatric
Open Access
- 26 February 2019
- journal article
- review article
- Published by Informa UK Limited in Expert Review of Vaccines
- Vol. 18 (3), 209-223
- https://doi.org/10.1080/14760584.2019.1580578
Abstract
Introduction: Hepatitis A, caused by hepatitis A virus (HAV), is primarily transmitted via the fecal/oral route either through ingestion of contaminated food and water or through direct contact with an infectious person. Prevalence of hepatitis A is strongly correlated with socioeconomic factors, decreasing with increased socio-economic development, access to clean water and sanitation. Vaccination against HAV should be part of a comprehensive plan for the prevention and control of viral hepatitis, either as part of regular childhood immunization programs or with other recommended vaccines for travelers. Areas covered: We present here evidence for the immunogenicity and safety of an inactivated HAV pediatric vaccine (Avaxim® 80U Pediatric, Sanofi Pasteur), indicated for use in children aged 12 months to 15 years. Data evaluated are from trials undertaken during the clinical development of this vaccine, a systematic literature review and post-market pharmacovigilance. Expert opinion: The pediatric HAV vaccine is highly immunogenic and generates long-lasting protection against hepatitis A disease in children. The safety and immunogenicity data presented in this review suggest that the pediatric HAV vaccine is a valuable option in the prevention of HAV infection in children in many areas of the world where the disease remains a healthcare issue.Keywords
Funding Information
- Sanofi Pasteur
This publication has 52 references indexed in Scilit:
- Persistence of immunity from 1 year of age after one or two doses of hepatitis A vaccine given to children in ArgentinaHepatic Medicine: Evidence and Research, 2012
- Hepatitis A immunisation in persons not previously exposed to hepatitis ACochrane Database of Systematic Reviews, 2012
- Hepatitis A: Epidemiology and prevention in developing countriesWorld Journal of Hepatology, 2012
- Decline in HAV-associated fulminant hepatic failure and liver transplant in children in Argentina after the introduction of a universal hepatitis A vaccination programHepatic Medicine: Evidence and Research, 2011
- Successful Memory Response following a Booster Dose with a Virosome-Formulated Hepatitis A Vaccine Delayed Up to 11 YearsClinical and Vaccine Immunology, 2011
- Safety and Immunogenicity of a Single Administration of Live-attenuated Japanese Encephalitis Vaccine in Previously Primed 2- to 5-year-olds and Naive 12- to 24-month-oldsThe Pediatric Infectious Disease Journal, 2010
- LONG-TERM IMMUNITY AFTER TWO DOSES OF INACTIVATED HEPATITIS A VACCINE, IN ARGENTINEAN CHILDRENThe Pediatric Infectious Disease Journal, 2010
- Effectiveness of universal hepatitis A immunization of children in Minsk City, Belarus: four‐year follow‐upJournal of Viral Hepatitis, 2008
- Interchangeability of a hepatitis A vaccine second dose: Avaxim 80 following a first dose of Vaqta 25 or Havrix 720 in children in TurkeyEuropean Journal of Pediatrics, 2007
- Aventis Pasteur Vaccines Containing Inactivated Hepatitis A Virus: A Compilation of Immunogenicity DataEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004